Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate that 76 weeks of treatment with rosuvastatin calcium 2.5-20 mg results in no progression of coronary artery atherosclerotic volume as measured by intravascular ultrasonography (IVUS) imaging in hypercholesterolaemic subjects with coronary heart disease (CHD).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Shionogi
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Signed written informed consent,

• 20 to 75 years old,

• Plan to undergo coronary angiography (CAG) or Percutaneous coronary intervention (PCI) and LDL-C ≥ 140 mg/dL (untreated patients) or LDL-C ≥ 100 mg/dL (treated patients)

Exclusion Criteria:

• Acute myocardial infarction within 72 hours after the onset,

• Heart failure of New York Heart Association (NYHA) Class III or above,

• Serious arrhythmia,

• Being treated with LDL-apheresis

• History of serious reaction or hypersensitivity to other HMG-CoA reductase inhibitors.